Financial reports
10-K
2023 FY
Annual report
15 Feb 24
10-Q
2023 Q3
Quarterly report
1 Nov 23
10-Q
2023 Q1
Quarterly report
3 Aug 23
10-Q
2023 Q1
Quarterly report
8 May 23
ARS
2022 FY
Annual report to shareholders
28 Apr 23
10-K
2022 FY
Annual report
15 Mar 23
10-Q
2022 Q3
Quarterly report
14 Nov 22
10-Q
2022 Q2
Quarterly report
9 Aug 22
10-Q
2022 Q1
Quarterly report
10 May 22
10-K
2021 FY
Annual report
17 Mar 22
Current reports
8-K
Prelude Therapeutics Reports Full Year 2023 Financial Results and Outlines Key Objectives for 2024
15 Feb 24
8-K
Prelude Therapeutics Announces $25 Million Private Placement
11 Dec 23
8-K
Prelude Announces Strategic Pipeline Progress and Updates, including its Partnership with AbCellera, and Reports Third Quarter Financial Results
1 Nov 23
8-K
Prelude Therapeutics Announces Second Quarter 2023 Financial Results and Provides Corporate Update
3 Aug 23
8-K
Submission of Matters to a Vote of Security Holders
21 Jun 23
8-K
Regulation FD Disclosure
1 Jun 23
8-K
Prelude Therapeutics Announces Launch of Proposed Public Offering
19 May 23
8-K
Other Events
17 May 23
8-K
Prelude Therapeutics Announces First Quarter 2023 Financial Results and Operations Update
8 May 23
8-K
Entry into a Material Definitive Agreement
15 Mar 23
Registration and prospectus
S-3
Shelf registration
15 Feb 24
S-8
Registration of securities for employees
15 Feb 24
424B5
Prospectus supplement for primary offering
19 May 23
FWP
Free writing prospectus
18 May 23
424B5
Prospectus supplement for primary offering
17 May 23
424B5
Prospectus supplement for primary offering
15 Mar 23
S-8
Registration of securities for employees
15 Mar 23
S-8
Registration of securities for employees
17 Mar 22
S-3
Shelf registration
12 Nov 21
S-8
Registration of securities for employees
16 Mar 21
Proxies
DEFA14A
Additional proxy soliciting materials
28 Apr 23
DEF 14A
Definitive proxy
28 Apr 23
PRE 14A
Preliminary proxy
18 Apr 23
DEFA14A
Additional proxy soliciting materials
29 Apr 22
DEF 14A
Definitive proxy
29 Apr 22
DEFA14A
Additional proxy soliciting materials
29 Apr 21
DEF 14A
Definitive proxy
29 Apr 21
Other
EFFECT
Notice of effectiveness
26 Nov 21
CORRESP
Correspondence with SEC
22 Nov 21
UPLOAD
Letter from SEC
19 Nov 21
EFFECT
Notice of effectiveness
7 Jan 21
CORRESP
Correspondence with SEC
4 Jan 21
CORRESP
Correspondence with SEC
4 Jan 21
UPLOAD
Letter from SEC
23 Dec 20
EFFECT
Notice of effectiveness
25 Sep 20
CERT
Certification of approval for exchange listing
24 Sep 20
CORRESP
Correspondence with SEC
22 Sep 20
Ownership